Clinical Trials Browser

Phase 1/2 × Squamous Cell Carcinoma of Head and Neck × Vorinostat × Clear all

NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Phase 1/2 Completed

50 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms